Cladribine to treat disease exacerbation after fingolimod discontinuation in progressive multiple sclerosis
نویسندگان
چکیده
منابع مشابه
Cladribine to treat disease exacerbation after fingolimod discontinuation in progressive multiple sclerosis
Rebound disease following cessation of disease modifying treatment (DMT) has been reported in people with both relapsing and progressive multiple sclerosis (pwRMS, pwPMS) questioning strict separation between these two phenotypes. While licensed DMT is available for pwRMS to counter rebound disease, no such option exists for pwPMS. We report on a pwPMS who developed rebound disease, with 45 Gad...
متن کاملA comparison of multiple sclerosis disease activity after discontinuation of fingolimod and placebo
BACKGROUND Cases of higher-than-expected disease activity have been reported following fingolimod discontinuation. OBJECTIVE The objective of this paper is to assess the risk of substantially higher-than-expected disease activity post-study drug discontinuation (SDD) at the individual patient level using data from the Phase III, placebo-controlled FREEDOMS and FREEDOMS II trials. METHODS Ba...
متن کاملProgressive Multifocal Leukoencephalopathy in a Multiple Sclerosis Patient Diagnosed after Switching from Natalizumab to Fingolimod
Background. Natalizumab- (NTZ-) associated progressive multifocal leukoencephalopathy (PML) is a severe and often disabling infectious central nervous system disease that can become evident in multiple sclerosis (MS) patients after NTZ discontinuation. Recently, novel diagnostic biomarkers for the assessment of PML risk in NTZ treated MS patients such as the anti-JC virus antibody index have be...
متن کاملFingolimod and multiple sclerosis
Neurology 2012;79:1942–1943 Unexpected consequences arise from our incomplete knowledge of the immune system. Who, for example, would have predicted that natalizumab, a monoclonal antibody targeting 4 integrin on leukocytes, would dramatically increase the risk of developing progressive multifocal leukoencephalopathy without causing notable immunosuppression? Thus, any new immunomodulatory ther...
متن کاملSensory-Neural Hearing Loss as an Early Rebound Relapse after Fingolimod Cessation in Multiple Sclerosis
Introduction: Multiple sclerosis (MS) is a lifelong disease of the brain and spinal cord. Fingolimod is an oral drug which modulates the S1P receptor and is used for relapsing remitting form of MS and can causes rebound activity if it is ceased even in a short period of washout time. Case Report: Here, we introduce a young girl, a known case of MS, who developed revers...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Annals of Clinical and Translational Neurology
سال: 2017
ISSN: 2328-9503
DOI: 10.1002/acn3.410